Current and Future Challenges In Drug Therapeutics for Sars-Cov-2 Infection in Covid-19 Pandemic |Biomedgrid

Pneumonia of unknown cause detected in Wuhan; China was first reported to the WHO Country Office in China on December 31 2019. Later, the causative agent of which was identified to be Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). On March 11, 2020, the pandemic caused by the SARS-CoV-2 was termed as COVID-19 by the World Health Organization (WHO), with the disease touching practically every country in the world. The SARS-CoV-2 infection is, although characterized by flu-like symptoms, the fast progression is attributed to the acute respiratory distress syndrome (ARDS) [1] or myocarditis [2]. Many other manifestations of the disease have been described in different patient groups across different countries. As of May 11, 2020, the total infections globally stand at 4,181,307 million people, with 283,880 deaths, and 1,493,556 recoveries. The take-home message is that despite the severity, there are more recoveries, as can be seen from currently active cases, which stand at 2,403,871, with 2,356,833 (98%) with mild presentation and 47,038 (2%) in severe or critical condition.